Effectiveness of drug therapies to treat or prevent respiratory syncytial virus infection-related morbidity.


Respiratory syncytial virus (RSV) infection causes a huge burden to the health service, as it results in a large number of in-patient days each year and increases the risk of asthma in childhood. In the acute phase, therapy is supportive as bronchodilators and corticosteroids have resulted, at best, only in short-term benefits; promising treatments for… (More)


  • Presentations referencing similar topics